Global Markets Direct's, 'Memory Impairment - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Memory Impairment, complete with latest updates, and special features on late-stage and discontinued projects. https://www.reportscorner.com/reports/15464/Memory-Impairment---Pipeline-Review,-H1-2013/

1. RC
Reports Corner
Memory Impairment - Pipeline Review, H1 2013

2. DescriptionDescription
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Memory Impairment - Pipeline Review,
H1 2013', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic
development for Memory Impairment, complete with latest
updates, and special features on late-stage and discontinued
projects.

3. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Memory Impairment - Pipeline Review,
H1 2013', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic
development for Memory Impairment, complete with latest
updates, and special features on late-stage and discontinued
projects. It also reviews key players involved in the therapeutic
development for Memory Impairment. Memory Impairment -
Pipeline Review, Half Year is built using data and information
sourced from Global Markets Direct's proprietary databases,
Company/University websites, SEC filings, investor presentations
and featured press releases from company/university sites and
industry-specific third party sources, put together by Global
Markets Direct's team.Note*: Certain sections in the report may be
removed or altered based on the availability and relevance of data
for the indicated disease.

4. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Scope- A snapshot of the global therapeutic scenario for Memory
Impairment.- A review of the Memory Impairment products under
development by companies and universities/research institutes
based on information derived from company and industry-specific
sources.- Coverage of products based on various stages of
development ranging from discovery till registration stages.- A
feature on pipeline projects on the basis of monotherapy and
combined therapeutics.- Coverage of the Memory Impairment
pipeline on the basis of route of administration and molecule
type.- Key discontinued pipeline projects.- Latest news and deals
relating to the products.Reasons to buy- Identify and understand
important and diverse types of therapeutics under development
for Memory Impairment.- Identify emerging players with potentially
strong product portfolio and design effective counter-strategies to
gain competitive advantage.-

5. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Plan mergers and acquisitions effectively by identifying players of
the most promising pipeline.- Devise corrective measures for
pipeline projects by understanding Memory Impairment pipeline
depth and focus of Indication therapeutics.- Develop and design
in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance
and expand business potential and scope.- Modify the therapeutic
portfolio by identifying discontinued projects and understanding
the factors that drove them from pipeline.

6. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Memory Impairment Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Memory Impairment 8
Memory Impairment Therapeutics under Development by Companies 10
Memory Impairment Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13

7. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Memory Impairment Therapeutics - Products under Development by Companies 15
Memory Impairment Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Memory Impairment Therapeutics Development 17
Neuralstem, Inc. 17
NeuroSearch A/S 18
M et P Pharma AG 19
Dart NeuroScience LLC 20
Omeros Corporation 21
Memory Impairment - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25

8. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Drug Profiles 27
pregnenolone succinate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
NSI-189 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
HT-0712 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Drug Targeting GPR83 - Drug Profile 32
Product Description 32

9. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Mechanism of Action 32
R&D Progress 32
levetiracetam - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
HT-1067 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
2-PMPA - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
meldonium - Drug Profile 36

10. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Product Description 36
Mechanism of Action 36
R&D Progress 36
NS-11394 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AC-253 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
rosiglitazone - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39

11. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Galanin Receptor 3 Program - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Novel 4-8 Program - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Novel 14- Program - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Phosphodiesterase 4 Backup Program - Drug Profile 43
Product Description 43
Mechanism of Action 43

12. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
R&D Progress 43
Novel 9-13 Program - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Drug Targeting Lipoprotein Lipase - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Memory Impairment Therapeutics - Drug Profile Updates 46
Memory Impairment Therapeutics - Dormant Products 48
Appendix 49
Methodology 49
Coverage 49

13. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

14. For more informationFor more information
Reports Cornerwww.reportscorner.com
For more information please visit our website
https://www.reportscorner.com/reports/15464/Memory-Impairment---Pipeline-
Review,-H1-2013/

15. Reports Corner
Thank YouThank You
www.reportscorner.com
RC
Contact us: contact@reportscorner.com